Healthcare entity
All 1 tracked stories fall under one category: regulation. Section 232 of the Trade Expansion Act is most often covered alongside 340B Drug Pricing Program, which appears in 1 of these 1 story. The 6 average consequence score is above the beat benchmark of 5.9 in the same window.
Last mentioned: Aug 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Section 232 of the Trade Expansion Act is most often covered alongside 340B Drug Pricing Program, which appears in 1 of these 1 story. The 6 average consequence score is above the beat benchmark of 5.9 in the same window. Each story carries 2 original sources on average, compared with 2.1 for the broader beat in this window. Section 232 of the Trade Expansion Act appears in 1 tracked Healthcare story from August 7, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Section 232 of the Trade Expansion Act. Shared-story counts are live from our verified record — not editorial picks.
With generic drugs accounting for 90% of U.S. prescriptions, the 100% tariff scheduled for 2028 threatens to narrow supply, potentially causing shortages of essential medicines. Price caps and hospital discount programs prevent cost pass-through, leaving healthcare systems vulnerable.
Section 232 of the Trade Expansion Act is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
